RxDoctor Payments Data

Muhammad Aslam, MD

Interventional Cardiology · South Bend, INNPI 1023053022

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,121 of the $13,615 with a category attached, or 67.0%. It is spread thinly across 36 manufacturers, the largest accounting for just 20.6%. Reporting peaked in 2022 at $3,715 and has fallen 53.7% since, to $1,720 in 2025.

$13,615in general payments, 2019–2025

Across 298 payments — averaging $45.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Edwards Lifesciences$3K
  • Abbott$2K
  • Medtronic$1K
  • Shockwave Medical, Inc$1K
  • Novartis$833
  • plus $3K from 30 others
$4,965in research payments, 2019–2025

Across 2 payments — averaging $2482.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$5K

What the payments were for

  • Travel & lodging$4,47233%
  • Food & beverage$9,12167%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,615 in reported general payments places this provider in the 70th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$223,707
Medicare patients
1,387
Services billed
3,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban365$418,914
EntrestoSacubitril/Valsartan134$153,244
XareltoRivaroxaban59$76,448
Repatha SureclickEvolocumab70$67,401
BrilintaTicagrelor80$47,638
FarxigaDapagliflozin Propanediol34$37,516
JardianceEmpagliflozin20$24,576
Praluent PenAlirocumab21$15,583
Atorvastatin Calcium1,161$8,883
Dofetilide50$8,077
Metoprolol Succinate668$6,146
Ezetimibe294$5,365
ClopidogrelClopidogrel Bisulfate652$5,118
Potassium Chloride294$4,394
Losartan Potassium513$4,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$418,914365 claims
NovartisEntresto$833$153,244134 claims
AstraZenecaBrilinta, Farxiga$70$85,154114 claims
Johnson & JohnsonXarelto$225$76,44859 claims
Boehringer IngelheimJardiance$38$24,57620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →